Vulnerable premature babies needing extra protection against RSV will receive a long-lasting single injection of nirsevimab, ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

Today, the Federation of Medical Women of Canada (FMWC) released its latest white paper through the Maternal RSV Task Force—a ...

A single, long-lasting jab that offers a “protective bubble” to premature babies from a common virus is set to be rolled out ...

Thousands of premature babies in the UK can now be protected against a common winter virus which can cause a dangerous lung ...

NHS Scotland will offer the new drug to protect babies born before 32 weeks against respiratory syncytial virus.